260 related articles for article (PubMed ID: 11364324)
1. FDA community meeting May 16: clinical trials and viral load. Food and Drug Administration.
AIDS Treat News; 1997 May; (No 270):3. PubMed ID: 11364324
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials and viral load: statement for FDA community meeting May 16. Food and Drug Administration.
James JS
AIDS Treat News; 1997 May; (No 271):1-4. PubMed ID: 11364367
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy in HIV/AIDS: update from San Francisco.
Laurence J
AIDS Read; 2000 Mar; 10(3):133-4. PubMed ID: 10758008
[No Abstract] [Full Text] [Related]
4. Therapies. Confronting the limits of success.
Cohen J
Science; 2002 Jun; 296(5577):2320-4. PubMed ID: 12089422
[No Abstract] [Full Text] [Related]
5. FDA evaluates accelerated approval process. Food and Drug Administration.
Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
[TBL] [Abstract][Full Text] [Related]
6. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
Feigal D
AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399
[TBL] [Abstract][Full Text] [Related]
7. AIDS researchers seek criteria for vaccines.
Check E
Nature; 2003 May; 423(6936):107. PubMed ID: 12736647
[No Abstract] [Full Text] [Related]
8. Let there be drugs.
Gilden D
GMHC Treat Issues; 1996 Feb; 10(2):1, 13-6. PubMed ID: 11363380
[TBL] [Abstract][Full Text] [Related]
9. On approval.
Huff B
GMHC Treat Issues; 2001 Oct; 15(10):5-8. PubMed ID: 11727570
[No Abstract] [Full Text] [Related]
10. FDA workshop on clinical trial design, September 6-7--registration by Aug. 18. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Aug; (no 228):5-6. PubMed ID: 11362627
[TBL] [Abstract][Full Text] [Related]
11. Symptom-reduction trials at FDA clinical trials workshop. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Sep; (no 231):7. PubMed ID: 11362873
[TBL] [Abstract][Full Text] [Related]
12. Experimental drug quickly suppresses HIV.
AIDS Read; 2005 Apr; 15(4):150. PubMed ID: 15844233
[No Abstract] [Full Text] [Related]
13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
14. FDA notifications. NRTI Emtriva receives FDA approval.
AIDS Alert; 2003 Oct; 18(10):131-2. PubMed ID: 14686301
[TBL] [Abstract][Full Text] [Related]
15. FDA reform in Congress: AIDS community absent. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Apr; (no 220):4-5. PubMed ID: 11362320
[TBL] [Abstract][Full Text] [Related]
16. FDA clarifies rules, allows combining antiretrovirals in clinical trials. Food and Drug Administration.
AIDS Treat News; 1999 Nov; (No 331):5-6. PubMed ID: 11367127
[TBL] [Abstract][Full Text] [Related]
17. FDA notifications. New antiretroviral guidelines issued.
AIDS Alert; 2005 Jan; 20(1):11-2. PubMed ID: 15717358
[No Abstract] [Full Text] [Related]
18. AIDS task force grapples with faster access to protease drugs.
Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Mar; 1(2):6-11. PubMed ID: 11362314
[TBL] [Abstract][Full Text] [Related]
19. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration.
Dalmau D; Klimkait T; Telenti A
Antivir Ther; 2005; 10(7):867-72. PubMed ID: 16312184
[TBL] [Abstract][Full Text] [Related]
20. FDA notifications. FDA postpones CCR5 Antagonist Review Group meeting.
AIDS Alert; 2006 Jan; 21(1):11-2. PubMed ID: 16470945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
